Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Marcum LLP Presentation June 2012
19 slides from Biorestorative Therapies's conference presentation, Jun 19, 2012
Slide 1: BioRestorative Therapies, Inc. Marcum LLP Presentation
biorestordtlve BioRestorative Therapies, Inc. OTCQB: BRTX Marcum LLP Presentation June 2012 biorest
Slide 2: Forward Looking Statements
Forward Looking Statements I penne tay Soest sta te sey oe ‘Therapies, Inc. the: Company’ to develop its adult stem cell business, the future of euragara Srcngen gavel “ten tammtauars ieee aU RarG ARR a Ma oi tices RNR rere ay ie nee ces eee Se ay Senin MING seagate wis cae pen See by such forward-l
Slide 3: About Us
About Us “it’s Aboutthe Science” + BioRestorative Therapies, Inc.’ s (“BRT”) goal is to become a leader in developing medical procedures using cell and tissue protocols, primarily involving adult stem cells (non-embryonic), and allowing patients to undergo cellular-based treatments. + BRT’ s scienti
Slide 4: Our Business
Our Business BRT is developing three business initiatives: — brtxDISC ™ Program (Disc implanted Stem Cells) + Seekingto offera non-surgical reatmentforthe cure andrelief from Disc disease (bulging andhemiated discs) + Addresses gap between non-invasive and invasive procedures — representing a large
Slide 5: brtxDISC Program
brixDISC™ Program * Minimally invasive procedure offering an altemative to Surgical intervention, addressing the large gap that Curtenily exists in disc treatments between non-surgical andsurgical therapies = Possibly eliminates surgeryinmany cases = Provides a substantially more effectve treatment
Slide 6: brtxDISC Business Model
brtxDISC™ Business Model ‘Reduce liability and riskby allowing skilled physiciansto perform the procedure Become @ manufacturing hub for cellular culturing to provide cell product Zan Sell Medical Kits: BRT laboratory will provide cultured cells ar neededfortreatments: Medical Kitincludes: » Deliver
Slide 7: Proprietary Delivery System
Proprietary Delivery System + Novel medical device (patent pending) allows for precise delivery of ‘stem cells in disc region where tear occurred ‘Advances inner catheter ‘Advances guide canula vicrestoie
Slide 8: brtxDISC Patient Success
brtxDISC™ Patient Success Problem: Chronicbackandleg pain dueto lumbar discbulge ‘Treatment: brixDISC™ minimally invasive procedure ‘Outcom Patient’ s symptoms eliminated and MRI shows significant eduction in size of disc bulge just 3 months afterthe brtxDISC™ procedure {URI Before Treatment {URI 2
Slide 9: brtxDISC Target Market
brtxDISC™ Target Market + Inthe U.S. — About 500,000 herniated and bulging disc related surgeries per year — About 300,000 spine fusions peryear — About 200,000 disc fusions per year + By capturing less than 1% of this market, BRT can become very profitable vicrestordfie
Slide 10: ThermoStem Program
ThermoStem™ Program + ThermoStem™ is designed to develop treatments using brown fat stem cells for metabolic disorders and obesity focusing on potentially preventing the ‘onsetof Type 2 Diabetes “Good Fat’ (brown adipose tissue) vs. “Bad Fat" (white adipose tissue) Recent studies show that brown fat
Slide 11: ThermoStem Program
ThermoStem™ Program
Slide 12: Brown Fat Advantages
Brown Fat Advantages + Brown fatis a groundbreaking research initiative because: — Thermogenesis (creation of heat) — has been shown to increase caloric Buming and induce weight loss — Dissolves or absorbs the bad “white fat” — much of which we are trying to reduce — Reduces glucose and lipids — may
Slide 13: Brown Fat Approach
Brown Fat Approach Since 1999, the FDAnas not approved a drug to treat obesity* Brown Fat provides a cellular approach that recent scientific publications have shown to potentially leadto a treatmentfor metabolic disorders and weightloss ERT is simultaneously adcressing three areas of potential trea
Slide 14: Brown Fat — Preclinical Data
1 ATI 5 of afl Glu~ctel mg/ Glut mg/dL Weight ctrl Weight tx at ‘em em Baseline Mth = 2Mth Mth Gluctrl wget 9847 10549 10946 ©1547 Glu-tergiat 9648 10247 10345 10344 Weight—ctr wt5 ite © sate | aad Weight—t« em 247 3045 3644 3845 Brown Fat — Preclinical Data Baseline =amth 2mth mamth 4amth ame ists
Slide 15: Target Market
Target Market Diabetes ~ Prevalence: 25.8 million children and adults in the United States—8.3% of the population—have diabetes. — New Cases: 1.9 million new cases of diabetes were diagnosedin People aged 20 years andolderin 2010. ~ Projection: One study showed that there will be 53.1 million Americ
Slide 16: BRT's Stem Pearls, LLC subsidiary offers plant stem cell based beauty care products
+ BRT’s Stem Pearls, LLC subsidiary offers plant stem cell based beauty care products for cosmetic treatment through web-based rogram: wiww.stempearis.com + Cell-based cosmetic treatment _ that harnesses the natural power derived from a Unique apple plantstem cell * Consists of four products: Apple
Slide 17: Stock Data
Stock Data Ticker Symbol: BRTX Exchange oTcaB Stock Price (6/15/12) $0.0235 Market Cap (6/15/12) $15.4M Shares Outstanding (5/9/12): 655M Float: 100.4M
Slide 18: Highlights
Highlights + Adultstem cell-based therapies the next generation of medical treatments + Efficientand Economical Research and Science + Hybrid business model with short and ong term revenue streams and goals * Proof of Concept - “Proven” technology that could offer a minimally invasive adult stem cel
Slide 19: Thank You
Thank You Company Contact: Investor Contact: BioRestorative Therapies, Inc. KCSA Strategic Communications Mark Weinreb, CEO PhilCarlson/ Josh Dver 555 Heritage Drive, Suite 130 880 Third Avenue, 6th Floor Jupiter, FL 33458 NewYork, NY 10022 Phone: (212) 896-1233 /1239 Phone: (561) 904-6070 Email: pc
BioRestorative Therapies — Marcum LLP Presentation June 2012 on 6ix